Key compounds such as 3-Benzoyl-2,4(1H,3H)-Pyrimidinedione were screened and validated for their binding affinity to oral cancer-related proteins AURKA, CDK1, and EGFR-2, demonstrating potential for drug development. Here, CDK1 is linked to lip and oral cavity carcinoma.